EFM
AVBP icon

E Fund Management’s ArriVent BioPharma AVBP Stock Holding History

E Fund Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.8M Buy
109,328
+15,375
+16% +$454K 0.09% 108
2026
Q1 		$2.17M Buy
+93,953
New +$2.12M 0.06% 144

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

E Fund Management's AVBP Position: Q2 2026 in Review

E Fund Management increased its ArriVent BioPharma (AVBP) stake by 16% in Q2 2026, buying an estimated $454K and bringing the position to 109,328 shares worth $3.8M. The position accounts for 0.09% of the portfolio, ranked #108.

E Fund Management first reported a position in AVBP in Q1 2026 and has held it in 2 quarters since. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • E Fund Management held 109,328 shares of ArriVent BioPharma worth $3.8M as of Q2 2026.
  • E Fund Management bought 15,375 ArriVent BioPharma shares in Q2 2026, an estimated $454K.
  • ArriVent BioPharma made up 0.09% of E Fund Management's portfolio in Q2 2026, its #108 holding.
  • E Fund Management first reported a position in ArriVent BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.